Confirming the Clinical Utility of OCT-Angiography with the new 3D PAR (Projection Artifact Removal) Technology from Optovue
With years of experience using AngioVue OCTA, and numerous peer-reviewed publications, Prof. Souied and Dr Miere are recognized as having played a pivotal role in the clinical validation of OCTA.
sponsored by Optovue
With over three years of experience using AngioVue OCTA, and numerous peer-reviewed publications, Prof. Souied and Dr Miere are recognized as having played a pivotal role in the clinical validation of OCTA.
The advent of 3D PAR for the AngioVue system is an important development for OCTA technology because the qualitative interpretation and subsequent quantification of retinal pathologies are greatly impacted by removing projection artifacts from the deeper retinal layers and the choroid. Prof. Souied will explain how OCTA for AMD and Diabetic Retinopathy will be redefined, while Dr Miere will illustrate the impact of 3D PAR in other retinal conditions.
